ORTEXORTEX News
Tracking UVSP? Get live short interest, options flow, and signals on ORTEX.Sign up free →
UV
Trader NoteUVSP

UVSP Shorts Build Ahead of Next Week's Earnings

Edited by Peter Hillerberg3 min readdata as of 19 Oct 2026, 17:35

Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish

ShareXLinkedInReddit

Univest Financial enters its October 28 earnings release with short sellers quietly adding exposure and the stock nursing a one-month loss even as the broader week turned mildly positive.

The short interest story is the most notable tension here. Shorts have grown by 17.4% over the past week, pushing the position to 3.3% of free float. That follows a 9.6% build over the prior month. The ORTEX short score has ticked up to 36.8 from 34.8 a week ago, a modest but steady drift higher. The borrow market tells a different story, however: availability is essentially unlimited, with over 12.7 million shares available against roughly 938,000 shorted. Cost to borrow is near the floor at 0.66%, despite rising 53% from a month-ago trough. This is not a squeeze setup. The short build looks like a considered pre-earnings hedge rather than a conviction directional trade, and the ease of borrow means adding or covering costs almost nothing.

Options positioning reinforces that read of low-conviction hedging. The put/call ratio is running at 0.09, slightly below its 20-day average of 0.10 and near the lower end of recent ranges. That is an unusually call-heavy skew for a stock heading into a print, though the very thin options market on UVSP means these readings carry less weight than they would for a more liquid name. The z-score of negative 0.58 suggests no unusual defensive positioning. On balance, the options market is not amplifying the short-side signal.

The Street view is cautious but has been drifting constructively upward. Keefe Bruyette & Woods, the only consistent voice on UVSP, has maintained a Market Perform rating while raising its target three times in the past year, most recently to $47 after the July results. The mean target is $45.50, a roughly 10% premium to the current $41.25. All recent analyst moves have been target increases with no rating changes, a pattern that describes measured optimism rather than a strong directional call. The stock's factor profile reflects the same ambivalence: the dividend score ranks in the 77th percentile and days-to-cover ranks 81st, but EPS surprise sits in the 27th percentile and forward earnings momentum ranks 31st, suggesting the income case is cleaner than the growth case.

The company's own FDIC call report data adds some colour ahead of next week. Net loans and leases have grown for three consecutive quarters, and total assets hit a record high for any second quarter since 2024 at $8.17 billion. These are balance sheet expansion signals, not yet validated as leading indicators for reported net income (the ORTEX Alt Data layer has not yet accumulated enough history to test whether the FDIC data leads Univest's reported figures), but they point to the bank continuing to grow its book into the Q3 period the upcoming print covers.

Insider activity from the 90-day window is net negative at roughly $1.3 million of selling. Two directors sold in August at prices around $41.70 to $43.00, and the June cluster of executive sales was largely the mechanical kind: option exercises immediately followed by same-day open-market sales by the CFO, CRO and CEO. None of the recent sales were flagged under 10b5-1 plans. BlackRock remains the largest institutional holder at 12.4% of shares, having added 306,000 shares in the most recent reported quarter. FMR and American Century also added meaningfully over the same period. Passive accumulation from the index crowd provides a structural floor, but the director selling at current prices is worth noting alongside the building short position.

Closing at $41.25 after a flat week in a mildly rising peer group (CCNE gained 2.5%, GSBC added 1.7%), Univest heads into its October 28 release with shorts at a six-week high, insiders having sold at prices modestly above current levels, and a balance sheet that has been expanding. What to watch is whether Q3 net interest margin and loan growth figures confirm or complicate the cautious analyst read that has accompanied each of this year's earnings-day target upgrades.

Stocks in this article

See the live data behind this article on ORTEX.

Open UVSP on ORTEX →

How this article was generated

Generated
19 Oct 2026, 17:35
Data as of
19 Oct 2026, 17:35
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.